（文章来源：证券日报） 证券日报网讯 9月19日晚间，海辰药业发布公告称，公司于近日收到国家药品监督管理局核准签发的 《药品注册证书》，药品名称：硫代硫酸钠注射液。 ...

Group 1 - Honghe Technology plans to increase capital by 300 million yuan to its wholly-owned subsidiary Huangshi Honghe through debt-to-equity conversion, raising its registered capital from 700 million yuan to 1 billion yuan [1] - Huaxia Happiness has completed debt restructuring amounting to approximately 192.67 billion yuan, with a total of 24 billion yuan in overdue debts as of August 31 [1] - Chengyi Pharmaceutical's controlling shareholder plans to reduce its stake by up to 1.18%, amounting to 387,560 shares [1][2] Group 2 - Yuanwang Valley received a warning letter from the Shenzhen Securities Regulatory Bureau for failing to halt trading when its controlling shareholder's stake changed to a multiple of 5% [2] - Gongjin Co. received government subsidies of 8.9 million yuan, accounting for 11.13% of its latest audited net profit [3] - Maiwei Biotech's application for the listing of 9MW0813 injection has been accepted by the National Medical Products Administration [4] Group 3 - Jianfeng Group plans to repurchase shares worth between 20 million and 40 million yuan at a maximum price of 12.42 yuan per share [6] - Ankai Micro plans to invest 20 million yuan to acquire a 4% stake in Shiqi Future [7] - Pinming Technology's stock will continue to be suspended as it is actively pursuing a significant matter that may lead to a change in control [8] Group 4 - China Communications has signed new contracts worth 256.34 billion yuan from January to August, with domestic contracts totaling 206.05 billion yuan [18] - Round Express reported a revenue of 5.39 billion yuan in August, a year-on-year increase of 9.82% [38] - China Pacific Insurance's original insurance premium income reached 217.05 billion yuan from January to August, up 13.2% year-on-year [39] Group 5 - *ST Chuangxing's chairman is under investigation, and the general manager will act as the chairman during this period [40] - Fengshan Group signed a technical development contract with Tsinghua University for a project related to sodium-ion battery electrolytes [40] - Yongxin Optical stated that its optical components related to lithography machines account for less than 1% of its revenue [41] Group 6 - Tianyuan Dike's subsidiary received a government subsidy of 3.77 million yuan, representing 16.27% of its latest audited net profit [42] - Huaxiang Co. plans to issue convertible bonds to raise no more than 1.308 billion yuan for various projects [43] - Wolong Electric Drive reported that its robot-related products accounted for only 2.71% of total revenue in the first half of the year [44]

格隆汇9月19日丨海辰药业(300584.SZ)公布，近日收到国家药品监督管理局核准签发的《药品注册证 书》，药品名称：硫代硫酸钠注射液。本品适应症为：主要用于氰化物中毒，也可用于砷、汞、铅、 铋、碘等中毒。硫代硫酸钠被认为是硫氰酸酶（Rhodanese）催化的反应中的硫供体，从而增强氰化物 的内源性解毒作用。 ...

Core Viewpoint - Hainan Pharmaceutical has received approval from the National Medical Products Administration for the registration of Sodium Thiosulfate Injection, which is primarily used for cyanide poisoning and can also be used for poisoning from arsenic, mercury, lead, bismuth, and iodine [1]. Group 1 - The drug name is Sodium Thiosulfate Injection [1] - The primary indication for the drug is cyanide poisoning [1] - The drug is also applicable for other types of poisoning, including arsenic, mercury, lead, bismuth, and iodine [1] Group 2 - Sodium thiosulfate is considered a sulfur donor in the reaction catalyzed by rhodanese, enhancing the body's endogenous detoxification of cyanide [1]

人民财讯9月19日电，海辰药业（300584）9月19日公告，公司于近日收到国家药品监督管理局核准签发 的《药品注册证书》。药品名称为硫代硫酸钠注射液，规格：50ml:12.5g，本品适应症为：主要用于氰 化物中毒，也可用于砷、汞、铅、铋、碘等中毒。 ...